Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies

CA Cancer Journal for Clinicians

Volumn 68, Issue 6, 2018, Pages 488-505

  Mahvi, David A ^a   Liu, Rong ^a   Grinstaff, Mark W ^b   Colson, Yolonda L ^a   Raut, Chandrajit P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b USA   (United States)

Author keywords

breast cancer; drug delivery; local recurrence; lung cancer; mesothelioma; nanoparticles; peritoneal surface malignancies; polymers; rectal cancer; sarcoma

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; CELECOXIB; CETUXIMAB; CISPLATIN; DENDRIMER; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NANOPARTICLE; NELIPEPIMUT S; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PALBOCICLIB; PEMETREXED; POLYMER; TRASTUZUMAB;

BRACHYTHERAPY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CRYOABLATION; DRUG DELIVERY SYSTEM; HUMAN; HYDROGEL; LONG TERM SURVIVAL; MESOTHELIOMA; MORBIDITY; NON SMALL CELL LUNG CANCER; NONHUMAN; OUTCOME ASSESSMENT; PERITONEUM CANCER; PHOTODYNAMIC THERAPY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTON THERAPY; QUALITY OF LIFE; RECTUM CANCER; RETROPERITONEAL SARCOMA; REVIEW; SARCOMA; COMPLICATION; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM; ONCOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT OUTCOME; TRENDS; TUMOR RECURRENCE;

COMBINED MODALITY THERAPY; HUMANS; MEDICAL ONCOLOGY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 85055119198     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21498     Document Type: Review

References (141)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.
2. National Center for Health Statistics (US). Health, United States, 2016: With Chartbook on Long-Term Trends in Health. Report No. 2017–1232. Hyattsville, MD: National Center for Health Statistics; 2017.
3. Heriot AG, Tekkis PP, Darzi A, Mackay J. Surgery for local recurrence of rectal cancer. Colorectal Dis. 2006;8:733-747.
4. Sagar PM, Pemberton JH. Surgical management of locally recurrent rectal cancer. Br J Surg. 1996;83:293-304.
5. Palmer G, Martling A, Cedermark B, Holm T. A population-based study on the management and outcome in patients with locally recurrent rectal cancer. Ann Surg Oncol. 2007;14:447-454.
6. Cai Y, Li Z, Gu X, Fang Y, Ziang J, Chen Z. Prognostic factors associated with locally recurrent rectal cancer following primary surgery (review). Oncol Lett. 2014;7:10-16.
7. Harji DP, Sagar PM. Advancing the surgical treatment of locally recurrent rectal cancer. Br J Surg. 2012;99:1169-1171.
8. Fujita S, Mizusawa J, Kanemitsu Y, et al. Mesorectal excision with or without lateral lymph node dissection for clinical stage II/III lower rectal cancer (JCOG0212): a multicenter, randomized controlled, noninferiority trial. Ann Surg. 2017;266:201-207.
9. Kusters M, Marijnen CA, van de Velde CJ, et al. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol. 2010;36:470-476.
10. Sebag-Mentefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR10 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811-820.
11. Kusters M, Beets GL, van de Velde CJ, et al. A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence. Ann Surg. 2009;249:229-235.
12. Ho VP, Lee Y, Stein SL, Temple LK. Sexual function after treatment for rectal cancer: a review. Dis Colon Rectum. 2011;54:113-125.
13. Gu W, Wu S. Meta-analysis of defunctioning stoma in low anterior resection with total mesorectal excision for rectal cancer: evidence based on thirteen studies [serial online]. World J Surg Oncol. 2015;13:9.
14. Mrak K, Uranitsch S, Pedross F, et al. Diverting ileostomy versus no diversion after low anterior resection for rectal cancer: a prospective, randomized, multicenter trial. Surgery. 2016;159:1129-1139.
15. Phatak UR, Kao LS, You YN, et al. Impact of ileostomy-related complications on the multidisciplinary treatment of rectal cancer. Ann Surg Oncol. 2014;21:507-512.
16. Loos M, Quentmeier P, Schuster T, et al. Effect of preoperative radio(chemo)therapy on long-term functional outcome in rectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2013;20:1816-1828.
17. Marijnen CA, van de Velde CJ, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005;23:1847-1858.
18. Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch Colorectal Cancer Group study. J Clin Oncol. 2005;23:199-206.
19. Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513-518.
20. Masaki T, Takayama M, Matsuoka H, et al. Intraoperative radiotherapy for oncological and function-preserving surgery in patients with advanced lower rectal cancer. Langenbecks Arch Surg. 2008;393:173-180.
21. Dubois JB, Bussieres E, Richaud P, et al. Intra-operative radiotherapy of rectal cancer: results of the French multi-institutional randomized study. Radiother Oncol. 2011;98:298-303.
22. Kusters M, Velntini V, Calvo FA, et al. Results of the European pooled analysis of IORT-containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastasis. Ann Oncol. 2010;21:1279-1284.
23. Pilar A, Gupta M, Ghosh Laskar S, Laskar S. Intraoperative radiotherapy: review of techniques and results [serial online]. Ecancermedicalscience. 2017;11:750.
24. Camilleri-Brennan J, Steele RJ. The impact of recurrent rectal cancer on quality of life. Eur J Surg Oncol. 2001;27:349-353.
25. Tanis PJ, Doeksen A, van Lanschot JJ. Intentionally curative treatment of locally recurrent rectal cancer: a systematic review. Can J Surg. 2013;56:135-144.
26. Harris CA, Solomon MJ, Heriot AG, et al. The outcomes and patterns of treatment failure after surgery for locally recurrent rectal cancer. Ann Surg. 2016;264:323-329.
27. Hecht M, Buttner-Herold M, Erlenbach-Wunsch K, et al. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer. 2016;65:52-60.
28. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567-575.
29. Fisher B, Anderson S, Bryant J, et al. Twenty-Year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233-1241.
30. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927-933.
31. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-575.
32. Mieog JS, van derHage JA, van deVelde CJ. Preoperative chemotherapy for women with operable breast cancer [serial online]. Cochrane Database Syst Rev. 2007;2:CD005002.
33. Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol. 2014;21:704-716.
34. Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24:2028-2037.
35. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707-1716.
36. van Tienhoven G, Voogd AC, Peterse JL, et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer. 1999;35:32-38.
37. Lehman M, Hickey BE, Francis DP, See AM. Partial breast irradiation for early breast cancer [serial online]. Cochrane Database Syst Rev. 2014;6:CD007077.
38. Fredriksson I, Liljegren G, Arnesson LG, et al. Local recurrence in the breast after conservative surgery—a study of prognosis and prognostic factors in 391 women. Eur J Cancer. 2002;38:1860-1870.
39. Kauer-Dorner D, Potter R, Resch A, et al. Partial breast irradiation for locally recurrent breast cancer within a second breast conserving treatment: alternative to mastectomy? Results from a prospective trial. Radiother Oncol. 2012;102:96-101.
40. Aebi S, Gelber S, Anderson SJ, et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014;15:156-163.
41. Newman LA, Hunt KK, Buchholz T, et al. Presentation, management, and outcome of axillary recurrence from breast cancer. Am J Surg. 2000;180:252-256.
42. van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92:1143-1150.
43. Jacobson JA, Danforth DN, Cowan KH, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med. 1995;332:907-911.
44. Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000;18:2817-2827.
45. Cheng SH, Horng CF, Clarke JL, et al. Prognostic index score and clinical prediction model of local recurrence after mastectomy in breast cancer patients. Int J Radiat Oncol Biol Phys. 2006;64:1401-1409.
46. EBCTCG (Early, Breast Cancer Trialists’ Collaborative Group). Effect of radiotherapy after mastectomy and axially surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127-2135.
47. Willner J, Kiricuta IC, Kolbl O. Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis. Int J Radiat Oncol Biol Phys. 1997;37:853-863.
48. Wakeam E, Acuna SA, Keshavjee S. Chest wall resection for recurrent breast cancer in the modern era: a systematic review and meta-analysis. Ann Surg. 2018;267:646-655.
49. Borner M, Bacchi M, Goldhirsch A, et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol. 1994;12:2071-2077.
50. Sirohi B, Leary A, Johnston SR. Ipsilateral breast tumor recurrence: is there any evidence for benefit of further systemic therapy. Breast J. 2009;15:268-278.
51. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39:576-588.
52. Ruffie PA. Pleural mesothelioma. Curr Opin Oncol. 1991;3:328-334.
53. Rusch VW, Giroux D. Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database. Ann Cardiothorac Surg. 2012;1:438-448.
54. Batirel HF. Extrapleural pneumonectomy (EPP) vs pleurectomy decortication (P/D). Ann Transl Med. 2017;5:232-239.
55. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620-626.
56. Sharkey AJ, Tenconi S, Nakas A, Waller DA. The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication. Eur J Cardiothorac Surg. 2016;49:1632-1641.
57. Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24:1561-1567.
58. Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009;138:405-411.
59. Chang MY, Sugarbaker DJ. Innovative therapies: intraoperative intracavitary chemotherapy. Thorac Surg Clin. 2004;14:549-556.
60. Lang-Lazdunski L, Bille A, Papa S, et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience. J Thorac Cardiovasc Surg. 2015;149:558-566; discussion 565–566.
61. Gomez DR, Hong DS, Allen PK, et al. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013;8:238-245.
62. Simone CB 2nd, Cengel KA. Photodynamic therapy for lung cancer and malignant pleural mesothelioma. Semin Oncol. 2014;41:820–830.
63. Friedberg JS, Simone CB 2nd, Culligan MJ, et al. Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years. Ann Thorac Surg. 2017;103:912-919.
64. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-2644.
65. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:1405-1414.
66. Burt BM, Ali SO, DaSilva MC, et al. Clinical indications and results after chest wall resection for recurrent mesothelioma. J Thorac Cardiovasc Surg. 2013;146:1373–1380.
67. Bissett D, Macbeth FR, Cram I. The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol (R Coll Radiol). 1991;3:315-317.
68. Abtin F, Quirk MT, Suh RD, et al. Percutaneous cryoablation for the treatment of recurrent malignant pleural mesothelioma: safety, early-term efficacy, and predictors of local recurrence. J Vasc Interv Radiol. 2017;28:213-221.
69. Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18:623-630.
70. Scherpereel A, Mazieres J, Greillier L, Do P, Bylicki O, Monnet I. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phase II trial [abstract]. J Clin Oncol. 2018;35(15 suppl):LBA8508.
71. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60:615-622.
72. Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after surgery for early stage lung cancer. an 11-year experience with 975 patients. Cancer 2009;115:5218-5227.
73. Wolf AS, Swanson SJ, Yip R, et al. The impact of margins on outcomes after wedge resection for stage I non-small cell lung cancer. Ann Thorac Surg. 2017;104:1171-1178.
74. Khullar OV, Liu Y, Gilliespie T, et al. Survival after sublobar resection versus lobectomy for clinical stage IA lung cancer: an analysis from the National Cancer Data Base. J Thorac Oncol. 2015;10:1625-1633.
75. Tandberg DJ, Tong BC, Ackerson BG, Kelsey CR. Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: a comprehensive review. Cancer 2018;124:667-678.
76. Schneider BJ, Daly ME, Kennedy EB, et al. Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: American Society of Clinical Oncology endorsement of the American Society for Radiation Oncology evidence-based guideline. J Clin Oncol. 2018;36:710-719.
77. Watanabe K, Tsuboi M, Sakamaki K, et al. Postoperative follow-up strategy based on recurrence dynamics for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2016;49:1624-1631.
78. Hung JJ, Hsu WH, Hsieh CC, et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax 2009;64:192-196.
79. Juloori A, Vassil AD, Woody NM, Stephans KL, Videtic GM. Managing local recurrence after primary resection of non-small cell lung cancer: the role for salvage stereotactic body radiation therapy [abstract]. Int J Radiat Oncol Biol Phys. 2016;96(suppl):E472. Abstract 3161.
80. Saynak M, Veeramachaneni NK, Hubbs JL, et al. Local failure after complete resection of N0–1 non-small cell lung cancer. Lung Cancer 2011;71:156-165.
81. Choi MS, Park JS, Kim HK, et al. Analysis of 1,067 cases of video-assisted thoracic surgery lobectomy. Korean J Thorac Cardiovasc Surg. 2011;44:169-177.
82. NSCLC Meta-Analysis Collaborative Group. Preoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014;383:1561-1571.
83. Endo C, Sakurada A, Notsuda H, et al. Results of a long-term follow-up of patients with completely resected non-small cell lung cancer. Ann Thorac Surg. 2012;93:1061-1068.
84. Chuang JC, Liang Y, Wakelee HA. Neoadjuvant and adjuvant therapy for non-small cell lung cancer. Hematol Oncol Clin North Am. 2017;31:31-44.
85. Digesu CS, Hachey KJ, Gilmore DM, et al. Long-term outcomes after near-infrared sentinel lymph node mapping in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2018;155:1280-1291.
86. Fernando HC, Landreneau RJ, Mandrekar SJ, et al. Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small cell lung cancer. J Clin Oncol. 2014;32:2456-2462.
87. American Cancer Society. Cancer Facts & Figures 2017. Atlanta, GA: American Cancer Society; 2017.
88. Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2009;27:31-37.
89. Gronchi A, Strauss DC, Miceli R, et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS). A report on 1007 patients from the Multi-Institutional Collaborative RPS Working Group. Ann Surg. 2016;263:1002-1009.
90. Stoeckle E, Coindre JM, Bonvalot S, et al. French Federation of Cancer Centers Sarcoma Group. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer 2001;92:359-368.
91. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238:358-370.
92. van Houdt WJ, Zaidi S, Messiou C, Thway K, Strauss DC, Jones RL. Treatment of retroperitoneal sarcoma: current standards and new developments. Curr Opin Oncol. 2017;29:260-267.
93. Fairweather M, Gonzalez RJ, Strauss D, Raut CP. Current principles of surgery for retroperitoneal sarcomas. J Surg Oncol. 2018;117:33-41.
94. Gronchi A, Miceli R, Colombo C, et al. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. Ann Oncol. 2012;23:1067-1073.
95. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415-423.
96. Woll PJ, Reichardt P, Le Cesne A, et al. ORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13:1045-1054.
97. Raut CP, Pisters PW. Retroperitoneal sarcomas: combined-modality treatment approaches. J Surg Oncol. 2006;94:81-87.
98. Pawlik TM, Pisters PW, Mikula L, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol. 2006;13:508-517.
99. Roeder F, Krempien R. Intraoperative radiation therapy (IORT) in soft-tissue sarcoma [serial online]. Radiat Oncol. 2017;12:20.
100. Tseng WH, Martinez SR, Do L, Tamurian RM, Borys D, Cancer RJ. Lack of survival benefit following adjuvant radiation in patients with retroperitoneal sarcoma: a SEER analysis. J Surg Res. 2011;168:e173-e180.
101. Angele MK, Albertsmeier M, Prix NJ, et al. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study. Ann Surg. 2014;260:749-754.
102. Colombo C, Baratti D, Kusamura S, Deraco M, Gronchi A. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) and isolated perfusion (ILP) interventions in sarcoma. J Surg Oncol. 2015;111:570579.
103. Trans-Atlantic RPS Working Group. Management of recurrent retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol. 2016;23:3531-3540.
104. Ryan CW, Merimsky O, Agulnik M, et al. PICASSO III: a phase III placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma. J Clin Oncol. 2016;24:3898-3905.
105. Nathenson MJ, Conley AP, Sausville E. Immunotherapy: a new (and old) approach to treatment of soft tissue and bone sarcomas. Oncologist. 2018;23:71-83.
106. Coccolini F, Gheza F, Lotti M, et al. Peritoneal carcinomatosis. World J Gastroenterol. 2013;19:6979-6994.
107. Gonzalez-Moreno S, Gonzalez-Bayon LA, Ortega-Perez G. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol. 2010;2:68-75.
108. Glehen O, Gilly FN, Boutitie F, et al. French Surgical Association. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients. Cancer. 2010;116:5608-5618.
109. Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol. 2013;130:493-498.
110. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449-2456.
111. Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22:1686-1693.
112. Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma—results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211-218.
113. Mehta SS, Gelli M, Agarwal D, Goere D. Complications of cytoreductive surgery and HIPEC in the treatment of peritoneal metastases. Indian J Surg Oncol. 2016;7:225-229.
114. Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatments: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release. 2012;159:14-26.
115. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery [serial online]. Front Pharmacol. 2015;6:286.
116. Dicheva BM, ten Hagen TL, Schipper D, et al. Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes. J Control Release. 2014;195:37-48.
117. Huang YW, Cambre M, Lee HJ. The toxicity of nanoparticles depends on multiple molecular and physicochemical mechanisms [serial online]. Int J Mol Sci. 2017;18:E2702.
118. Gil-Gil MJ, Bellet M, Morales S, et al. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Res Treat. 2015;151:597-606.
119. Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci. 2014;6:139-150.
120. Wang M, Li Y, HuangFu M, et al. Pluronic-attached polyamidoamine dendrimer conjugates overcome drug resistance in breast cancer. Nanomedicine (Lond). 2016;11:2917-2934.
121. Amreddy N, Babu A, Panneerselvam J, et al. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimernanoparticles for lung cancer treatment. Nanomedicine. 2018;14:373-384.
122. Conti DS, Brewer D, Grashik J, Avasarala S, da Rocha SR. Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Mol Pharm. 2014;11:1808-1822.
123. Overchuk M, Zheng G. Overcoming obstacles in the tumor microenvironment: recent advancements in nanoparticle delivery for cancer theranostics. Biomaterials. 2017;156:217-237.
124. Bahrami B, Hojjat-Farsani M, Mohammadi H, et al. Nanoparticles and targeted drug delivery in cancer therapy. Immunol Lett. 2017;190:64-83.
125. Kaira K, Tomizawa Y, Imai H, et al. Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2017;79:165-171.
126. Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122:111-115.
127. Stapleton S, Jaffray D, Milosevic M. Radiation effects on the tumor microenvironment: implications for nanomedicine delivery. Adv Drug Deliv Rev. 2017;109:119-130.
128. Liu R, Colby AH, Gilmore D, et al. Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma. Biomaterials. 2016;102:175-186.
129. Liu R, Gilmore DM, Zubris KA, et al. Prevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles. Biomaterials. 2013;34:1810-1819.
130. Zubris KA, Khullar OV, Griset AP, et al. Ease of synthesis, controllable sizes, and in vivo large animal lymph migration of polymeric nanoparticles. Chem Med Chem. 2010;5:1435-1438.
131. Colby AH, Liu R, Schulz MD, et al. Two-step delivery: exploiting the partition coefficient concept to increase intratumoral paclitaxel concentrations in vivo using responsive nanoparticles [serial online]. Sci Rep. 2016;6:18720.
132. Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR. Panyam J CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release. 2013;171:280-287.
133. Xing WK, Saho C, Qi ZY, Yang C, Wang Z. The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis. Drug Des Devel Ther. 2015;9:3341-3348.
134. Liu R, Wolinsky JB, Walpole J, et al. Prevention of local tumor recurrence following surgery using low-dose chemotherapeutic polymer films. Ann Surg Oncol. 2010;17:1203-1213.
135. Liu R, Wolinsky JB, Catalano PJ, et al. Paclitaxel-eluting polymer film reduces locoregional recurrence and improves survival in a recurrent sarcoma model: a novel investigational therapy. Ann Surg Oncol. 2012;19:199-206.
136. Kaplan JA, Liu R, Freedman JD, et al. Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes. Biomaterials 2016;76:273-281.
137. Norouzi M, Nazari B, Miller DW. Injectable hydrogel-based drug delivery systems for local cancer therapy. Drug Discov Today. 2016;21:1835-1649.
138. Lei N, Gong C, Qian Z, et al. Therapeutic application of injectable thermosensitive hydrogel in preventing local breast cancer recurrence and improving incision wound healing in a mouse model. Nanoscale. 2012;4:5686-5693.
139. Yun Q, Wang SS, Xu S, et al. Use of 5-fluorouracil loaded micelles and cisplatin in thermosensitive chitosan hydrogel as an efficient therapy against colorectal peritoneal carcinomatosis [published online ahead of print October 20, 2016]. Macromol Biosci. https://doi.org/10.1002/mabi.201600262
140. Opitz I, Erne BV, Demirbas S, et al. Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: a preclinical study. J Thorac Cardiovasc Surg. 2011;141:165-171.
141. Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release. 2015;219:500-518.